Fig. 2
AIL inhibited melanoma progression in vitro and in vivo. A PIG1, SK-MEL-5 and SK-MEL-28 cells were treated with the indicated concentrations of AIL for 0, 24, 48 and 72 h. Cell viability was determined with the CCK-8 reagent. The average IC50 values for AIL in PIG1, SK-MEL-5 and SK-MEL-28 cells are shown. B JB6, B16-F10 and YUMM1.7 cells were treated with the indicated concentrations of AIL for 0, 24, 48 and 72 h. Cell viability was determined with the CCK-8 reagent. The average IC50 values for AIL in JB6, B16-F10 and YUMM1.7 cells are shown. C Wound healing assay in SK-MEL-5 and B16-F10 cells treated with AIL. Data are shown as the mean ± SEM, n = 3; *p < 0.05, **p < 0.01 and ***p < 0.001. D Transwell invasion assay in SK-MEL-5 and B16-F10 cells treated with AIL. Data were shown as the mean ± SEM of three independent experiments. Data are shown as the mean ± SEM, n = 3; *p < 0.05, **p < 0.01 and ***p < 0.001. E-H C57BL/6 mice were implanted with 5 × 105 B16-F10 cells and received PBS or AIL (0.5 and 5 mg/kg). (E) Photographs of tumor samples isolated from C57BL/6 mice treated with PBS or AIL. F Tumor weight. G Volume changes in the tumor. H The body weight curves of the mice measured every two days. Data are shown as the mean ± SEM, n = 6; *p < 0.05, **p < 0.01 and ***p < 0.001